

## ANNUAL BURDEN ESTIMATES

| Statement                                 | Number of respondents | Number of responses per respondent | Average burden hours per response | Total burden hours |
|-------------------------------------------|-----------------------|------------------------------------|-----------------------------------|--------------------|
| Case Plan .....                           | 701,461               | 1                                  | 2.60                              | 1,823,900          |
| Estimated total annual burden hours ..... | .....                 | .....                              | .....                             | 1,823,900          |

*Additional Information:* Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: [grjohnson@acf.hhs.gov](mailto:grjohnson@acf.hhs.gov).

*OMB Comment:* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office

of Management and Budget, Paperwork Reduction Project, Attn: Desk Officer for ACF, e-mail address: [katherine\\_t.\\_astrich@omb.eop.gov](mailto:katherine_t._astrich@omb.eop.gov).

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 04-16053 Filed 7-14-04; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Proposed Information Collection Activity; Comment Request

#### Proposed Projects

*Title:* State Plan for Child Support Under Title IV-D of the Social Security Act (OCSE-100 and OCSE-21-U4).

*OMB No.:* 0970-0017.

*Description:* The state plan serves as a contract between the Office of Child Support Enforcement and state IV-D agencies in outlining the activities the state will perform as required by law in order for States to receive Federal funds for child support enforcement.

*Respondents:* State IV-D Agencies.

## ANNUAL BURDEN ESTIMATES

| Instrument                                | Number of respondents | Number of responses per respondent | Average burden hours per response | Total burden hours |
|-------------------------------------------|-----------------------|------------------------------------|-----------------------------------|--------------------|
| State Plan (OCSE-100) .....               | 54                    | 6                                  | .5                                | 162                |
| State plan transmittal (OCSE-21-U4) ..... | 54                    | 6                                  | .25                               | 81                 |
| Estimated total annual burden hours ..... | .....                 | .....                              | .....                             | 243                |

In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: [grjohnson@acf.hhs.gov](mailto:grjohnson@acf.hhs.gov). All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including

whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: July 9, 2004.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 04-16054 Filed 7-14-04; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2004D-0160]

#### Withdrawal of Guidance Document on Use of Unapproved Hormone Implants in Veal Calves

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; withdrawal.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing a guidance for industry (#172) entitled "Use of Unapproved Hormone Implants in Veal Calves." This guidance, which was issued on April 2, 2004, is being withdrawn because the policy contained within it only applied to veal calves presented for slaughter prior to June 6, 2004.

**FOR FURTHER INFORMATION CONTACT:**

Gloria J. Dunnavan, Center for Veterinary Medicine (HFV-230), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-1166, e-mail: [gloria.dunnavan@fda.gov](mailto:gloria.dunnavan@fda.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** dated April 8, 2004 (69 FR 18594), FDA announced the availability of a guidance for industry (#172) entitled "Use of Unapproved Hormone Implants in Veal Calves." This guidance outlined special measures to ensure the safety of veal in response to the identified illegal use of unapproved hormone implants in veal calves. The policy outlined in this guidance only applied to veal calves presented for slaughter prior to June 6, 2004. Therefore, the guidance is no longer relevant and is being withdrawn. Because there is no approved animal drug application providing for the use of these implants in veal calves, such use is illegal. Under section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b), use of an unapproved new animal drug results in the drug being unsafe, and, therefore, the drugs are adulterated under section 501(a)(5) of the act (21 U.S.C. 351(a)(5)). In addition, food that bears or contains these drugs is adulterated under section 402(a)(2)(C)(ii) of the act (21 U.S.C. 342(a)(2)(C)(ii)).

Dated: July 9, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 04-16036 Filed 7-14-04; 8:45 am]

**BILLING CODE 4160-01-S**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Health Resources and Services Administration**

#### **Advisory Commission of Childhood Vaccines Request for Nominations for Voting Members**

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Health Resources and Services Administration (HRSA) is requesting nominations to fill three vacancies on the Advisory Commission on Childhood Vaccines (ACCV). The ACCV was established by Title XXI of the Public Health Service Act (the Act), as enacted by Public Law (Pub. L.) 99-660 and as subsequently amended, and advises the Secretary of Health and Human Services (the Secretary) on issues related to implementation of the

National Vaccine Injury Compensation Program (VICP).

**DATES:** The agency must receive nominations on or before August 16, 2004.

**ADDRESSES:** All nominations are to be submitted to the Acting Director, Division of Vaccine Injury Compensation (DVIC), Special Programs Bureau, HRSA, Parklawn Building, Room 16C-17, 5600 Fishers Lane, Rockville, Maryland 20857.

**FOR FURTHER INFORMATION CONTACT:** Ms. Cheryl A. Lee, Principal Staff Liaison, Policy Analysis Branch, DVIC, at (301) 443-2124 or email: [CLee@hrsa.gov](mailto:CLee@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** Under the authorities that established the ACCV, the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463) and section 2119 of the Act, 42 U.S.C. 300aa-19, as added by Pub. L. 99-660 and amended, HRSA is requesting nominations for three voting members of the ACCV.

The ACCV advises the Secretary on the implementation of the VICP. The activities of the ACCV include: Recommending changes in the Vaccine Injury Table at its own initiative or as the result of the filing of a petition; advising the Secretary in implementing section 2127 regarding the need for childhood vaccination products that result in fewer or no significant adverse reactions; surveying Federal, State, and local programs and activities related to gathering information on injuries associated with the administration of childhood vaccines, including the adverse reaction reporting requirements of section 2125(b); advising the Secretary on the methods of obtaining, compiling, publishing, and using credible data related to the frequency and severity of adverse reactions associated with childhood vaccines; and recommending to the Director of the National Vaccine Program that vaccine safety research be conducted on various vaccine injuries.

The ACCV consists of nine voting members appointed by the Secretary as follows: Three health professionals, who are not employees of the United States Government and have expertise in the health care of children, the epidemiology, etiology and prevention of childhood diseases, and the adverse reactions associated with vaccines, at least two shall be pediatricians; three members from the general public, at least two shall be legal representatives (parents or guardians) of children who have suffered a vaccine-related injury or death; and three attorneys, at least one shall be an attorney whose specialty includes representation of persons who

have suffered a vaccine-related injury or death, and one shall be an attorney whose specialty includes representation of vaccine manufacturers. In addition, the Director of the National Institutes of Health, the Assistant Secretary for Health, the Director of the Centers for Disease Control and Prevention, and the Commissioner of the Food and Drug Administration (or the designees of such officials) serve as nonvoting ex officio members.

Specifically, HRSA is requesting nominations for three voting members of the ACCV representing: (1) A pediatrician, who has expertise in the health care of children, the epidemiology, etiology, and prevention of childhood diseases; (2) an attorney whose specialty includes representation of persons who have suffered a vaccine-related injury or death; and (3) a legal representative (parent or guardian) of a child who has suffered a vaccine-related injury or death. Nominees will be invited to serve a 3-year term beginning January 1, 2005, and ending December 31, 2007.

Interested persons may nominate one or more qualified persons for membership on the ACCV. Nominations shall state that the nominee is willing to serve as a member of the ACCV and appears to have no conflict of interest that would preclude the ACCV membership. Potential candidates will be asked to provide detailed information concerning consultancies, research grants, or contracts to permit evaluation of possible sources of conflicts of interest. A curriculum vitae or resume should be submitted with the nomination.

The Department of Health and Human Services has special interest in assuring that women, minority groups, and the physically disabled are adequately represented on advisory committees; and therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or disabled candidates.

Dated: July 8, 2004.

**Elizabeth M. Duke,**  
*Administrator.*

[FR Doc. 04-16039 Filed 7-14-04; 8:45 am]

**BILLING CODE 4165-15-P**